Foreign cancer experts criticize the Israeli research team's claims that they have developed a concept that will open the way to cancer treatment, and one US expert will reject it as "another long, wrong, irresponsible and ultimately cruel false promise for cancer patients. ”
The head of the research firm announced the Israeli time on Tuesday that it had not published research in medical journals, as is the norm, as it "cannot afford" to do so, but its previous results – clinical trials have been "very good." who were contacted by the Israeli Times refused to comment on this request, some because they were not familiar with research.
"We are working on a complete cancer treatment," said Ilan Morad, Nes Zion-based startup Accelerated Evolution Biotechnologies Ltd. (AEBi) Executive Director and Founder, interviewing with Israeli times on Tuesday. earlier this week to a post in Jerusalem. "We still have a long way to go, but in the end we believe we will have to cure all types of cancer patients and with very little side effects."
Morad added that in "years", the company could start treating patients as part of the clinical trials that it wanted to start if it increased the funds. The family of developed molecules in its seemingly centered pathway has been tested in Israeli pre-clinical studies with human cancer cells in the laboratory and in mice. cancer such as lung cancer, colon cancer and head and neck cancer.
Several hospitals and experts in Israel refused to comment on the allegations, some said they did not have direct information on the study. Other foreign experts warned of researchers' claims.
Dr. Leonard Lichtenfeld, Deputy Head of the State Bureau of the American Cancer Society, noted on Tuesday that, although Israeli scientists have worked with an "interesting approach to intervening in cancer cell operation", their research is "apparently not published in scientific literature where it could be reviewed, supported and / or criticize knowledgeable colleagues. ”
“We all have the hope that cure for cancer can be found and found quickly. This is certainly possible, this approach may work, ”he wrote in a blog report entitled“ Cure Cancer? Not so fast."
“However, as experience has taught us so many times, the difference from a successful mouse experiment to effective, cost-effective use of laboratory concepts to help cancer patients in bed is actually a long and treacherous journey filled with unforeseen and unexpected obstacles. ”
“It may be time to prove the benefits of this new approach to cancer treatment. And unfortunately, based on other similar antiviral claims for cancer treatment, chances are that it won't be successful. ”
Lichtenfeld added: “We hope that this approach will also bear fruit and be successful. At the same time, we must always pay attention to the fact that the process of getting this treatment from mouse to person is not always a simple and simple journey. ”
Dr. Ben Neel, director of Perlmutter Cancer Center NYU Langone Health, told The New York Post that "cancer has several diseases and it is highly unlikely that this company has found a" cure "for cancer more than there is one cure for infections. ”
He said that "this statement is likely to be another long, false, irresponsible, and ultimately cruel false promise to cancer patients."
Publish or … explore?
Morad said the AEBi team chose to use their small tools to do more research than publish their research in medical journals.
The company wants to focus on "driving research and developing more targeted peptides." It takes a lot of work and we are small businesses, ”he said in the Israeli era. “We can't afford it. Publishing the article takes a lot of effort and resources, and we can't afford it.
He added: "If we were a big company with great funding, it would be the first thing we would do. If I have $ 100,000, what do I spend? He asked. “Promoting Research and Searching for More and More Targeted Peptides or Doing Many Experiments for Article Writing? What would you do if you had to choose? "
In the traditional development process, medical researchers who discover the discovery collect their material and submit it to legitimate medical journals, hoping that the editorial boards of magazines will approve their findings and publish a discovery. The higher the prestige of the publication, the greater the value of the discovery. Researchers do not have to pay for legal medical journals to publish their findings.
"Octopus" Armed with Peptides
The drug the company hopes to develop will be a personalized medicine that will be adapted to each patient's specific types of cancer, ”said Morad. "Each person will receive the medicine for a particular cancer."
The treatment that a company calls MuTaTo (Multi-Target Toxin) is a family of molecules that are armed with peptides that can interact with different protein expression proteins. Instead of targeting just one type of protein, molecules have the ability to target multiple proteins at the same time, said Morad. "We are creating multiple attacks on cancer," he said.
"Think of the octopus," he said. "In this case, octopus is a molecule, and at the end of each hand there are peptides that interact with proteins and inhibit their function." This interaction allows "toxic peptides" attached to many octopus hands to enter the cancer cell and destroy it from the inside.
The results of pre-clinical studies, Morad, were "very good", which shows that molecules have the ability to kill cancer cells, targeting them rather than other healthy cells. “The effect is specific for cancer cells, leaving other non-cancer cells, so the side effects will be much smaller. It will have side effects at the level of ibuprofen or total aspirin.
The company is now the concept of patenting, he said. So far, funding comes from private investors.
Morad founded AEBi in 2000 and previously worked as a researcher at Peptor Ltd., a Bio-pharmaceutical company Rehovot, which in 2003 gained green light for merging with German biopharmaceutical company DeveloGen. Other team members are Dan Aridor, Chairman of the Board, specialized in financing Columbia Business School, according to the company's website.
The third member mentioned on the website is Hanan Itzhaki, chief operating officer of the company. Itzhaki has been working for the company since 2002 and previously worked for SIA Rehovot based InSight Pharmaceutical Ltd. He holds post-doctoral degree in the Horticultural Department of Purdue University of India and holds a doctorate from the Faculty of Agriculture of the Jewish University of Jerusalem.
Morad said the team is now trying to promote their research and get into clinical research as soon as possible.
The US Food and Drug Administration determines drug development and process procedures: “Before drug testing in humans, a drug company or sponsor carries out laboratory and animal tests to discover how the medicine works and whether it could be safe and work well for people. Afterwards, a series of tests are launched to determine whether the medicine is safe for the treatment of the disease and whether it provides real health benefits. ”